How EDCs Promote Endometriosis
Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus — on the ovaries, fallopian tubes, and pelvic peritoneum. This tissue responds to hormonal signals, growing and bleeding with the menstrual cycle. EDCs in hair relaxers that mimic estrogen can promote the growth and survival of endometrial implants, worsening the condition.
Symptoms and Impact
Endometriosis causes chronic pelvic pain, extremely painful periods, pain during intercourse, painful bowel movements and urination, and infertility (affecting 30–50% of women with the condition). The disease significantly impacts quality of life and can require multiple surgeries.
Legal Considerations for Endometriosis Claims
Endometriosis claims are not in the bellwether pool (which is limited to cancer cases), but they are part of the broader MDL 3060. Endometriosis claims generally have lower projected values than cancer claims but are still compensable — particularly when surgical intervention was required.
Medical Documentation
Endometriosis is definitively diagnosed through laparoscopic surgery and pathological confirmation. Key evidence includes surgical records, pathology reports, fertility treatment records, and documentation of chronic pain management and its impact on daily life.
Scientific Evidence
Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health Study
Bertrand KA, Coogan PF, Palmer JR (2023). Environmental Research
View on PubMed→Use of Straighteners and Other Hair Products and Incident Uterine Cancer
Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ (2022). Journal of the National Cancer Institute
View on PubMed→Use of Hair Products in Relation to Ovarian Cancer Risk
White AJ, Sandler DP, et al. (2021). Carcinogenesis
View on PubMed→Frequently Asked Questions
Related Pages
Hair Relaxer Uterine Cancer
Uterine cancer is the primary injury in the hair relaxer litigation. The NIH Sister Study found a 155% increased risk (HR 2.55) for frequent users. Approximately 67,000 Americans are diagnosed with uterine cancer annually.
Hair Relaxer Ovarian Cancer
The Sister Study found hair relaxer users face a 2.19x increased risk of ovarian cancer. Ovarian cancer is often called the "silent killer" because symptoms are vague until advanced stages, making early detection difficult.
Hair Relaxer Settlement Amounts
No hair relaxer cases have settled or gone to trial yet. Attorney estimates project $90,000–$1,000,000+ depending on injury type and severity. Bellwether trials expected in 2027 will establish actual case values.
L'Oréal Hair Relaxer Lawsuit
L'Oréal is the primary defendant in the hair relaxer MDL through its subsidiary SoftSheen-Carson, maker of Dark & Lovely and Optimum Care. L'Oréal is the world's largest beauty company with €38+ billion in annual revenue.
Revlon Dark and Lovely Lawsuit
Revlon is a defendant in the hair relaxer MDL despite filing bankruptcy in 2022. Revlon maintains insurance coverage and allocated ~$44 million for hair relaxer claims in its reorganization plan. Products include Creme of Nature and Revlon Realistic.
Hair Relaxer Chemical Exposure
Hair relaxers contain at least 45 endocrine-disrupting chemicals across 10 chemical classes. 84% of these chemicals are NOT listed on product labels. The chemicals enter the body through the scalp, whose protective barrier is compromised by the relaxing process itself.
Hair Relaxer Lawsuit Black Women
Hair relaxer lawsuits disproportionately affect Black women, who were the primary marketing target, comprise 60% of affected users, and face twice the uterine cancer mortality rate of white women. This is both a product liability and a racial justice case.
Hair Relaxer Cancer Lawsuits Lawsuit
Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. The NIH/NIEHS Sister Study (2022) found that women who frequently used these products faced more than double the risk of uterine cancer. Over 14,700 lawsuits are consolidated in MDL 3060 in the Northern District of Illinois, with bellwether trials expected in 2027. The litigation disproportionately affects Black women, who were the primary marketing target and comprise approximately 60% of affected users.
View full case overview